Brian A. Van Tine, MD, PhD

Articles

Translating Metabolic Therapies Into Sarcoma

December 18th 2024

Brian A. Van Tine, MD, PhD, of Washington University of St. Louis and Siteman Cancer Center, discusses how to translate metabolic therapies into sarcoma management.

Dr Van Tine on the SPEARHEAD-1 Trial of Afami-Cel in Advanced Synovial Sarcoma

August 17th 2023

Brian A. Van Tine, MD, PhD, discusses findings from the overall survival analysis of the phase 2 SPEARHEAD-1 trial in patients with advanced synovial sarcoma.

Dr Van Tine on Investigating Cabozantinib With PD-1 and CTLA-4 Inhibition in Sarcoma

June 9th 2023

Brian A. Van Tine, MD, PhD, discusses the rationale for launching a randomized phase 2 trial investigating cabozantinib combined with nivolumab and ipilimumab vs cabozantinib alone in metastatic soft tissue sarcoma and discusses key findings from the trial.

Dr Van Tine on the Investigation of KB-0742 in R/R Solid Tumors

June 6th 2023

Brian A. Van Tine, MD, PhD, discusses the ongoing evaluation of the CDK9 inhibitor KB-0742 in a phase 1 trial in patients with relapsed/refractory solid tumors or non-Hodgkin lymphoma, detailing the key enrollment criteria.

Dr. Van Tine on the Methods Utilized in the Spearhead 1 Trial in Sarcoma Subtypes

February 10th 2022

Brian A. Van Tine, MD, PhD, discusses the methods utilized in the phase 2 Spearhead 1 trial evaluating afamitresgene autoleucel in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.

Dr. Van Tine on Next Steps With Catequentinib in Soft Tissue Sarcoma

October 14th 2021

Brian A. Van Tine, MD, PhD, discusses next steps with catequentinib (Anlotinib) in soft tissue sarcoma.

Dr. Van Tine on Outcomes With Catequentinib in Synovial Sarcoma

August 24th 2021

Brian A. Van Tine, MD, PhD, discusses outcomes with catequentinib in the treatment of patients with synovial sarcoma.

Dr. Van Tine on the Rationale to Evaluate Catequentinib in Synovial Sarcoma

July 27th 2021

Brian A. Van Tine, MD, PhD, discusses the rationale to evaluate catequentinib in synovial sarcoma.

Dr. Van Tine on Next Steps With ADP-A2M4 in Advanced Solid Tumors

May 31st 2020

Brian A. Van Tine, MD, PhD, discusses next steps with ADP-A2M4 SPEAR T cells in advanced solid tumors.

Dr. Van Tine on Collaboration and Clinical Trials in Uterine Sarcoma

July 21st 2019

Brian A. Van Tine, MD, PhD, discusses collaboration within the sarcoma field and the importance of clinical trials for advancing treatment.

Dr. Van Tine on Trabectedin for Leiomyosarcoma and Liposarcoma

June 3rd 2015

Brian A. Van Tine, MD, PhD, Assistant Professor Department of Medicine Siteman Cancer Center, Washington University School of Medicine, discusses trabectedin (Yondelis) for the treatment of soft tissue sarcomas.

Dr. Van Tine on Sequencing Therapies in GIST

March 27th 2015

Brian Van Tine, MD, PhD, assistant professor of medicine, Division of Oncology, Section of Medical Oncology, Washington University School of Medicine, discusses sequencing in gastrointestinal stromal tumors (GIST).

Dr. Van Tine Discusses Potential Novel Treatment Modalities for Sarcoma

July 23rd 2014

Brian A. Van Tine, MD, PhD, assistant professor, Washington University School of Medicine in St. Louis, discusses some potential novel treatment modalities for the treatment of sarcoma.

Academic Medical Oncologists Complement Role of Community Oncologists in Sarcoma Treatment

October 24th 2013

One of the privileges of working in an academic medical center is the luxury of being able to subspecialize in the treatment of sarcoma. Nationwide, there may be 40 to 50 medical oncologists who focus on the treatment of adult soft tissue and bone sarcoma.

Dr. Van Tine on Identifying Biomarkers in Sarcomas

August 12th 2013

Brian A. Van Tine, MD, PhD, Assistant Professor, Washington University School of Medicine in St. Louis, discusses identifying biomarkers in sarcomas.

Dr. Van Tine on Arginine Deiminase for Sarcomas

June 11th 2013

Brian A. Van Tine, MD, PhD, Assistant Professor, Washington University School of Medicine in St. Louis, discusses the use of arginine deiminase (ADI-PEG20) for the treatment of sarcomas.